

Jeffrey A Tice

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7112540/publications.pdf>

Version: 2024-02-01

68
papers

4,649
citations

196777

29
h-index

156644

58
g-index

70
all docs

70
docs citations

70
times ranked

6097
citing authors

#	ARTICLE	IF	CITATIONS
1	Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population. <i>Journal of the National Cancer Institute</i> , 2022, 114, 676-685.	3.0	18
2	The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 385-394.	2.2	11
3	Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography. <i>JAMA Network Open</i> , 2022, 5, e222440.	2.8	21
4	Acceptability of an mHealth breast cancer risk-reduction intervention promoting risk assessment, education, and discussion of risk in the primary care setting. <i>MHealth</i> , 2021, 7, 0-0.	0.9	3
5	The effectiveness and value of novel treatments for cystic fibrosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 276-280.	0.5	4
6	Endogenous Progestogens and Colorectal Cancer Risk among Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1100-1105.	1.1	3
7	The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 528-532.	0.5	1
8	Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. <i>Npj Breast Cancer</i> , 2021, 7, 78.	2.3	12
9	Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry. <i>Npj Breast Cancer</i> , 2021, 7, 102.	2.3	4
10	Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The B ^{1/4} FIT Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2030-2037.	1.1	2
11	The effectiveness and value of belimumab and voclosporin for lupus nephritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1495-1499.	0.5	2
12	Comparing Mammographic Density Assessed by Digital Breast Tomosynthesis or Digital Mammography: The Breast Cancer Surveillance Consortium. <i>Radiology</i> , 2021, , 204579.	3.6	10
13	The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 528-532.	0.5	0
14	Medications for Primary Prevention of Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 291.	3.8	17
15	Breast Cancer Population Attributable Risk Proportions Associated with Body Mass Index and Breast Density by Race/Ethnicity and Menopausal Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2048-2056.	1.1	41
16	Vitamin D Does Not Prevent Cancer or Cardiovascular Disease: The VITAL Trial. <i>Journal of General Internal Medicine</i> , 2020, , 1.	1.3	14
17	Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women. <i>JAMA Network Open</i> , 2020, 3, e203645.	2.8	23
18	Abstract 2359: Endogenous progestogens and colorectal cancer risk among postmenopausal women. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
19	Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. <i>JAMA Network Open</i> , 2019, 2, e190035.	2.8	72
20	Validation of the breast cancer surveillance consortium model of breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 519-523.	1.1	55
21	An Intervention Tool to Increase Patient-Physician Discussion of Lifestyle Risk Factors for Breast Cancer. <i>Journal of Women's Health</i> , 2019, 28, 1468-1475.	1.5	5
22	Abstract 589: Circulating progesterone is associated with increased postmenopausal breast cancer risk: B-FIT cohort. , 2019, , .		1
23	Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. <i>JAMA Internal Medicine</i> , 2018, 178, 494.	2.6	36
24	Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. <i>JAMA Pediatrics</i> , 2018, 172, 1161.	3.3	69
25	Supplemental Breast Cancer Screening: A Density Conundrum. <i>Journal of General Internal Medicine</i> , 2017, 32, 593-594.	1.3	3
26	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw290.	3.0	171
27	Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 220-225.	0.5	67
28	Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw276.	3.0	55
29	Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 748.	3.8	130
30	Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 603-612.	1.1	22
31	Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. <i>PLoS ONE</i> , 2017, 12, e0168601.	1.1	16
32	Screening for Breast Cancer in Women With Dense Breasts. , 2016, , 241-263.		0
33	Effectiveness and Value of Integrating Behavioral Health Into Primary Care. <i>JAMA Internal Medicine</i> , 2016, 176, 691.	2.6	30
34	Breast cancer risk prediction using a clinical risk model and polygenic risk score. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 513-525.	1.1	129
35	Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 743.	3.8	286
36	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels. <i>JAMA Internal Medicine</i> , 2016, 176, 107.	2.6	41

#	ARTICLE	IF	CITATIONS
37	Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the Bâ¼FIT Cohort. Hormones and Cancer, 2016, 7, 49-64.	4.9	39
38	Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Internal Medicine, 2016, 176, 65.	2.6	118
39	Identifying Women With Dense Breasts at High Risk for Interval Cancer. Annals of Internal Medicine, 2015, 162, 673-681.	2.0	215
40	One versus Two Breast Density Measures to Predict 5- and 10-Year Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 889-897.	1.1	30
41	Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1419-1422.	1.1	18
42	The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. Journal of the National Cancer Institute, 2015, 107, .	3.0	174
43	Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1. JAMA Internal Medicine, 2015, 175, 1559.	2.6	9
44	The Effect of Change in Body Mass Index on Volumetric Measures of Mammographic Density. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1724-1730.	1.1	26
45	Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 3137-3143.	0.8	170
46	Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial. Breast, 2015, 24, 758-766.	0.9	25
47	The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir for Chronic Hepatitis C Virus Infection. JAMA Internal Medicine, 2014, 174, 1170.	2.6	17
48	Estrogen metabolism and breast cancer risk among postmenopausal women: a caseâ€“cohort study within B~FIT. Carcinogenesis, 2014, 35, 346-355.	1.3	57
49	Abstract 940: The contribution of common breast cancer susceptibility loci to the breast density and breast cancer association and the Breast Cancer Surveillance Consortium (BCSC) risk model. , 2014, , .		0
50	Abstract 1603: Estrogen metabolites and colorectal cancer risk in postmenopausal women in the Breast and Bone Follow-up to the Fracture Intervention Trial (Bâ¼FIT). , 2014, , .		0
51	Benign Breast Disease, Mammographic Breast Density, and the Risk of Breast Cancer. Journal of the National Cancer Institute, 2013, 105, 1043-1049.	3.0	99
52	Abstract B86: Estrogen metabolism and postmenopausal breast cancer risk in the Bâ¼FIT cohort. Cancer Prevention Research, 2012, 5, B86-B86.	0.7	0
53	The Vital Amines: Too Much of a Good Thing?. Archives of Internal Medicine, 2010, 170, 1631-3.	4.3	5
54	Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk. Journal of the National Cancer Institute, 2009, 101, 384-398.	3.0	226

#	ARTICLE	IF	CITATIONS
55	Mammographic density as a marker of breast cancer risk?. <i>Current Breast Cancer Reports</i> , 2009, 1, 175-180.	0.5	0
56	Screening and Prevention of Breast Cancer in Primary Care. <i>Primary Care - Clinics in Office Practice</i> , 2009, 36, 533-558.	0.7	24
57	Full-field digital mammography compared with screen-film mammography in the detection of breast cancer: rays of light through DMIST or more fog?. <i>Breast Cancer Research and Treatment</i> , 2008, 107, 157-165.	1.1	11
58	Introduction. <i>Journal of General Internal Medicine</i> , 2008, 23, 1-1.	1.3	20
59	Gastric Banding or Bypass? A Systematic Review Comparing the Two Most Popular Bariatric Procedures. <i>American Journal of Medicine</i> , 2008, 121, 885-893.	0.6	407
60	Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model. <i>Annals of Internal Medicine</i> , 2008, 148, 337.	2.0	450
61	Risk Factors for Mortality in Middle-aged Women. <i>Archives of Internal Medicine</i> , 2006, 166, 2469.	4.3	59
62	Prospective Breast Cancer Risk Prediction Model for Women Undergoing Screening Mammography. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1204-1214.	3.0	399
63	Mammographic Breast Density and the Gail Model for Breast Cancer Risk Prediction in a Screening Population. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 115-122.	1.1	219
64	Nipple Aspirate Fluid Cytology and the Gail Model for Breast Cancer Risk Assessment in a Screening Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 324-328.	1.1	58
65	The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. <i>American Journal of Medicine</i> , 2003, 114, 199-205.	0.6	82
66	Phytoestrogen Supplements for the Treatment of Hot Flashes: The Isoflavone Clover Extract (ICE) Study. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 207.	3.8	230
67	Cost-effectiveness of Homocysteine-Lowering Therapy to Prevent Coronary Heart Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 191.	3.8	0
68	Relation of Serum Ascorbic Acid to Mortality Among US Adults. <i>Journal of the American College of Nutrition</i> , 2001, 20, 255-263.	1.1	86